Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
GlaxoSmithKline has scored a Department of Defense contract worth up to $41 million over five years to develop a new class of antibiotics. Under the contract, GSK will identify antibacterials targeting gram-negative biothreats as well as conventional gram-negative hospital pathogens, which have become increasingly resistant to current treatments. Gram-negative bacteria, which include Pseudomonas, Klebsiella, and Acinetobacter, are particularly tricky to combat due to an outer membrane that can keep drugs from reaching the bacterial cell. GSK will work on developing drugs that can first penetrate that barrier and then kill the pathogen.
This article has been sent to the following recipient: